shares of reata pharmaceuticals inc were trading higher friday a day after the company said the us food and drug administration informed the company it doesnt plan to hold an advisory committee meeting in connection with its review of the new drug application for omaveloxolone to treat patients with friedreichs ataxia at 1134 am et shares of reata were trading 18 higher at 2956 per share volume at the time was just under 2 million shares the stocks 65day average volume is 785663 million the company said friedreichs ataxia is a rare genetic lifeshortening debilitating and degenerative neuromuscular disorder there are no approved therapies for the condition reata said